GlassScriptPhysician profile
Jonathan S Szeto
NPI 1780666818
$12,919.64
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,769 · 2020: $864 · 2021: $2,259 · 2022: $27.65.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $7,645.67 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,320.49 | 2019-2021 | |
| Abbvie INC. | $563.29 | 2019-2022 | |
| Novo Nordisk INC | $436.91 | 2019-2021 | |
| Pfizer INC. | $420.44 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $332.57 | 2019-2021 | |
| Amgen INC. | $263.98 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $256.95 | 2019-2021 | |
| Foundation Medicine, INC. | $202.16 | 2021 | |
| Novartis Pharmaceuticals Corporation | $190.98 | 2019-2021 | |
| Glaxosmithkline, LLC. | $181.02 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $154.06 | 2019-2021 | |
| Allergan, INC. | $153.99 | 2019-2020 | |
| Radius Health, INC. | $122.09 | 2019 | |
| Amarin Pharma, INC. | $121.78 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $120.60 | 2019-2021 | |
| Eisai INC. | $106.07 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $48.24 | 2021 | |
| Sanofi Pasteur INC. | $36.23 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.11 | 2021 | |
| Sunovion Pharmaceuticals INC. | $28.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $26.11 | 2020 | |
| Biogen, INC. | $25.83 | 2021 | |
| Alkermes, INC. | $24.50 | 2019 | |
| Janssen Biotech, INC. | $17.07 | 2021 | |
| Boston Scientific Corporation | $16.95 | 2021 | |
| Phadia US INC. | $16.17 | 2021 | |
| Esperion Therapeutics, INC. | $16.01 | 2021 | |
| Astellas Pharma US INC | $13.49 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.89 | 2020 | |
| Ironwood Pharmaceuticals, INC | $11.11 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Szeto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.